Immunotherapy patient communities and the behavioral signals that precede clinical action
Immunotherapy patient communities generate thousands of behavioral signals weeks before clinical action occurs. These signals, from search patterns to peer-to-peer disclosure timing, contain intelligence that pharma companies, oncologists, and health plans consistently miss. VIOLET maps this behavioral layer and scores the underlying data so it can actually be used.
Cancer immunotherapy patients do not wake up one morning and decide to ask their oncologist about pembrolizumab. That conversation is preceded by weeks of behavioral signals: search queries, community forum posts, caregiver research sessions, and insurance navigation attempts. The clinical moment is the last event in a long behavioral sequence, not the first.
Most immuno-oncology intelligence platforms focus on what happens after a patient enters a clinical workflow. VIOLET focuses on what happens before.
How immunotherapy patient communities generate pre-clinical signals
Online patient communities for immunotherapy are not static support groups. They are real-time behavioral data environments. Patients and caregivers share treatment timelines, report side effects, compare infusion center experiences, and ask questions that reveal their position in the treatment decision process.
A caregiver searching "what happens if Keytruda stops working" is in a fundamentally different behavioral state than one searching "immunotherapy success rates for lung cancer." The first query signals a patient already on treatment who may be approaching a switch. The second signals someone still in the consideration phase.
These behavioral differences matter. They determine clinical trial eligibility windows, drug switching timelines, and the moments when patients are most receptive to new information. Yet most pharmaceutical and clinical trial recruitment strategies treat all immunotherapy interest signals as equivalent.
What are good signs immunotherapy is working?
Patients ask this question constantly in online communities, and the behavioral pattern around it is telling. Searches for "signs immunotherapy is working" spike between weeks 6 and 12 of treatment, which aligns with the first set of imaging scans most oncologists order after initiating checkpoint inhibitor therapy.
Clinically, positive indicators include tumor shrinkage on imaging, stable disease without progression, reduced tumor markers in blood work, and manageable side effect profiles. But from a behavioral intelligence perspective, the timing and frequency of this search reveals where a patient is in their treatment arc. A patient who stops searching for efficacy signals entirely may have received definitive news, positive or negative, and that silence is itself a data point.
What are the two checkpoints targeted by immunotherapy?
The two primary immune checkpoints targeted by current immunotherapy drugs are PD-1/PD-L1 and CTLA-4. PD-1 inhibitors like pembrolizumab (Keytruda) and nivolumab (Opdivo) block the interaction between PD-1 on T cells and PD-L1 on tumor cells, preventing the tumor from evading immune detection. CTLA-4 inhibitors like ipilimumab (Yervoy) work earlier in the immune activation process, releasing the brakes on T cell activation in lymph nodes.
Search volume data shows that patients rarely search for these mechanisms by their technical names. Instead, they search for brand names combined with their specific cancer type. This creates a behavioral map that ties drug awareness to tumor type, geography, and stage of diagnosis. VIOLET captures these patterns and scores them for data trust before any model or campaign uses them.
What are the behavioral changes in cancer patients?
Behavioral changes in cancer patients extend well beyond clinical symptoms. Patients undergoing immunotherapy show distinct digital behavior shifts: increased nighttime search activity (correlating with insomnia and anxiety), migration from general cancer forums to treatment-specific communities, and a measurable increase in searches related to financial toxicity and insurance coverage.
Caregiver behavior changes in parallel. Caregivers of immunotherapy patients search for side effect management guides, infusion scheduling logistics, and caregiver burnout resources at rates 3 to 4 times higher than caregivers of patients on traditional chemotherapy. This behavioral layer is invisible to EHR systems but clearly visible in community and search data.
For a deeper look at how behavioral patterns precede clinical contact, see The anxiety gap in cancer care: what patients search before they call a clinic.
What is the new cancer drug in 2026?
Several immunotherapy agents are expected to reach approval milestones in 2026. Bispecific antibodies, which simultaneously engage two targets, are the leading category. Drugs like tarlatamab (targeting DLL3 and CD3 for small cell lung cancer) and other bispecific T cell engagers are in late-stage trials with potential 2026 approval timelines.
Behavioral data already shows early awareness signals for these agents. Searches for "bispecific antibody cancer treatment" increased 140% between Q1 2024 and Q1 2025. VIOLET tracks these emerging awareness curves so pharma companies and trial sponsors can identify interest before it reaches oncology offices.
Key statistics
Immunotherapy patient behavioral data contains measurable, scorable intelligence that most organizations currently ignore.
Why data trust scoring matters for immunotherapy behavioral signals
Behavioral data from patient communities is powerful, but it is also fragile. A forum post from 2019 about a drug that has since changed its indication carries different weight than a post from last month. A search signal from a geography with no nearby infusion center means something different than the same signal from a major metro area.
This is why VIOLET does not just collect behavioral signals. It scores them. Every data point passes through the Data Trust Index, which evaluates Provenance, Consent, Recency, Quality, Concordance, Validation, Breadth, and Stability. Only data that meets trust thresholds enters downstream models.
Without this scoring layer, immunotherapy patient data becomes noise. With it, the data becomes intelligence that pharma companies can use for campaign timing, that trial sponsors can use for recruitment, and that health plans can use for care navigation. For more on how unscored data fails in production, read Why AI models trained on unscored health data will fail in production.
From behavioral signal to clinical action
The gap between a patient's first immunotherapy search and their first clinical conversation is where the most important decisions get shaped. Patients form opinions about treatment options, side effect tolerability, and even physician choice during this window. Caregivers build mental models of what to expect and what to fear.
Organizations that understand this window can meet patients and caregivers with accurate, trusted information at the moment it matters most. Organizations that ignore it are left reacting to decisions that were already made weeks earlier.
SuperTruth builds the data trust infrastructure that makes this intelligence usable. If you work in immuno-oncology and want to understand the behavioral signals your patients are generating before they reach your clinic or your trial site, contact Louis Simeonidis, SVP Commercial Operations, at louis@supertruth.ai or (215) 918-4140.
Further reading:
Jason Alan Snyder
Co-founder of SuperTruth and Artists & Robots, and an inventor on the Data Trust Index patents. Twenty-plus years building technology inside Interpublic Group. He writes here nearly every day on data trust, provenance, and what AI should be allowed to act on, and publishes essays on his Substack.
About SuperTruth · LinkedIn · Substack · jasonalansnyder.com
See it in practice
750+ cancer search terms. Live in production.
VIOLET maps behavioral signals 12–18 months before clinical presentation.